PRESOL | A | Research Activities Associated With the Immunization Via Mosquito Bite with Radiation-attenuated Plasmodium Falciparum Sporozoites (IMRAS) Clinical Trial.

FBO DAILY ISSUE OF APRIL 21, 2012 FBO #3801
SOLICITATION NOTICE

A -- Research Activities Associated With the Immunization Via Mosquito Bite with Radiation-attenuated Plasmodium Falciparum Sporozoites (IMRAS) Clinical Trial.

Notice Date: 4/19/2012
Notice Type: Presolicitation
NAICS: 541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Contracting Office: N62645 Naval Medical Logistics Command 693 Neiman Street Ft. Detrick, MD
ZIP Code: 00000
Solicitation Number: N6264512IMRAS
Response Due: 5/7/2012
Archive Date: 5/22/2012
Point of Contact: Thomas Hood 301-619-9236
Small Business Set-Aside: N/A
Description: The Naval Medical Logistics Command (NAVMEDLOGCOM) intends to award a sole source contract under the authority of FAR 6.302-1 to Seattle Biomedical Research Institute Seattle, WA 98109-5240, for the performance of research and development (R&D), in support of the Naval Medical Research Center (NMRC). This requirement is to conduct research activities associated with the immunization via mosquito bite with radiation-attenuated Plasmodium falciparum sporozoites (IMRAS) Clinical Trial. The estimated value of the contract is $1,900,000.00. The IMRAS Clinical trial is part of NMRC ™s œBiomarkers of protection in humans immunized with Plasmodium falciparum irradiated sporozoites malaria research project, which is being conducted under a Cooperative Development and Research Agreement signed between NMRC and the funder, the Bill and Melinda Gates Foundation (NMRC-12-3941). NMRC is joined under a Memorandum of Understanding by two additional Department of Defense activities “ the Walter Reed Army Institute of Research (WRAIR) and the US Army Medical Materiel Development Activity (USAMMDA) “ to address the research tasks under the CRADA. Additionally, an external collaborator is needed with expertise in the systems biology of malaria, as there is no federal partner with this capability. Seattle BioMed is well known globally for its strength in research on malaria, HIV, tuberculosis, and trypanosomiasis. Seattle BioMed ™s Malaria Program comprises five principal investigators who are key leaders in the fields of immunology, parasitology, systems biology, antigen discovery and whole sporozoite vaccines. The research capability of Seattle BioMed is sustained by multiple core facilities including DNA Sequencing, Proteomics, Flow Cytometry, Imaging, Protein Production, Bioinformatics and the Insectary. Of particular relevance to this contract, Seattle BioMed is the only institute in the world with infectious disease research and systems biology fully integrated in one building. All these strengths show that this laboratory is the only qualified laboratory that has the capability to carry out the work successfully. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All capability statements received by 9:00 AM Eastern Time, 07 May 2012 will be considered by the Government. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to NMLC-Research@med.navy.mil.
Web Link: FBO.gov Permalink
(https://www.fbo.gov/spg/DON/BUMED/N62645/N6264512IMRAS/listing.html)
Place of Performance: Address: Naval Medical Research Center; Zip Code: 503 Robert Grant Avenue
Record: SN02726133-W 20120421/120419235506-1a8720797f4720cd0deac6466ad7e0f3 (fbodaily.com)
Source: FedBizOpps Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's FBO Daily Index Page |

Loren Data's SAM Daily™

A -- Research Activities Associated With the Immunization Via Mosquito Bite with Radiation-attenuated Plasmodium Falciparum Sporozoites (IMRAS) Clinical Trial.